The global gastric motility disorder drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Gastric motility (or gastrointestinal motility) is the process by which food travels through the digestive tract through a series of muscular contractions called peristalsis. When someone has a gastric motility disorder, these contractions do not occur normally, and food is not able to pass through the intestines properly. These disorders are further responsible for a wide range of medical conditions such as gastroesophageal reflux disease (GERD), difficulty in swallowing, gastric problems, diarrhea or severe constipation, vomiting, abdominal pain, and bloating. Thus, in order to treat these wide range of medical conditions, the demand for gastric motility disorder drugs is likely to grow in the future years, thereby propelling the market growth.

Adding to this, the prevalence of gastroparesis and irritable bowel syndrome (IBS) is also associated with the gastric motility disorder. The rising geriatric population which is more prone to gastrointestinal disorders, and the shifting focus of global population toward preventive health management are also anticipated to spur the global digestive health enzymes market. The secretion of digestive enzymes generally reduces with age, which is responsible for poor digestion, frequent gastric discomfort, reduced food consumption, and even various other gastrointestinal disorders. Other factors that are anticipated to boost the market growth include the efficiency of these drugs in treating various conditions such as pancreatitis, exocrine pancreatic insufficiency, and pancreatic cancer. Thus, the growing burden of these diseases call for an effective solution such as gastric motility disorder drug.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Eli Lilly and Co., and Theravance, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Gastric Motility Disorder Drug Market Report by Segment

By Type

• Velusetrag

• Ipamorelin

• TD-8954

• Others

By Application

• Hospital

• Clinic

• Home Use

Global Gastric Motility Disorder Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa